Use of adeno-associated virus-mediated delivery of mutant huntingtin to study the spreading capacity of the protein in mice and non-human primates
Open Access
- 1 July 2020
- journal article
- research article
- Published by Elsevier in Neurobiology of Disease
- Vol. 141, 104951
- https://doi.org/10.1016/j.nbd.2020.104951
Abstract
No abstract availableFunding Information
- CAMS Innovation Fund for Medical Sciences
- SAFEA (G20190001626)
- National Natural Science Foundation of China (31970510)
- FRQS
- Desjardins bourse de prestige Didier Mouginot
- Fondation du CHU de Québec
- bourse d'excellence du Centre Thématique de Recherche en Neurosciences
- CHU
This publication has 52 references indexed in Scilit:
- A role of mitochondrial complex II defects in genetic models of Huntington's disease expressing N-terminal fragments of mutant huntingtinHuman Molecular Genetics, 2013
- PSD-95 expression controls l-DOPA dyskinesia through dopamine D1 receptor traffickingJournal of Clinical Investigation, 2012
- Fibrillar α-Synuclein and Huntingtin Exon 1 Assemblies Are Toxic to the CellsBiophysical Journal, 2012
- Axonal transport of adeno-associated viral vectors is serotype-dependentGene Therapy, 2012
- Huntington's disease: a clinical reviewOrphanet Journal of Rare Diseases, 2010
- Lentiviral Overexpression of GRK6 Alleviates l -Dopa–Induced Dyskinesia in Experimental Parkinson’s DiseaseScience Translational Medicine, 2010
- Cytoplasmic penetration and persistent infection of mammalian cells by polyglutamine aggregatesNature Cell Biology, 2009
- Therapeutic silencing of mutant huntingtin with siRNA attenuates striatal and cortical neuropathology and behavioral deficitsProceedings of the National Academy of Sciences, 2007
- Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal deathNature, 2004
- Delayed matching-to-sample, object retrieval, and discrimination reversal deficits in chronic low dose MPTP-treated monkeysBrain Research, 1993